Caspase substrates and inhibitors

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 8, 2013, Pages

  Porȩba, Marcin ^a   Strózyk, Aleksandra ^a   Salvesen, Guy S ^b   Dra̧g, Marcin ^a  

^a WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE INHIBITOR;

APOPTOSIS; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; FLUORESCENCE; GENETICS; INFLAMMATION; METABOLISM; PHYSIOLOGY; PROCEDURES; PROTEIN CONFORMATION; PROTEOMICS; TRENDS;

APOPTOSIS; CASPASE INHIBITORS; CASPASES; FLUORESCENCE; INFLAMMATION; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEOMICS; SUBSTRATE SPECIFICITY;

EID: 84879005856     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a008680     Document Type: Article

References (139)

1. Agard NJ, Maltby D, Wells JA. 2010. Inflammatory stimuli regulate caspase substrate profiles. Mol Cell Proteomics 9: 880-893.
2. Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK. 2008. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell 30: 11-25.
3. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J. 1996. Human ICE/CED-3 protease nomenclature. Cell 87: 171.
4. Asgian JL, James KE, Li ZZ, Carter W, Barrett AJ, Mikolaj-czyk J, Salvesen GS, Powers JC. 2002. Aza-peptide epox-ides: A new class of inhibitors selective for clan CD cys-teine proteases. J Med Chem 45: 4958-4960.
5. Auf Dem Keller U, Schilling O. 2010. Proteomic techniques and activity-based probes for the system-wide study of proteolysis. Biochimie 92: 1705-1714.
6. Bedner E, Smolewski P, Amstad P, Darzynkiewicz Z. 2000. Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): Correlation with DNA fragmentation. Exp Cell Res 259: 308-313.
7. Benkova B, Lozanov V, Ivanov IP, Mitev V. 2009. Evaluation of recombinant caspase specificity by competitive substrates. Anal Biochem 394: 68-74.
8. Berger AB, Sexton KB, Bogyo M. 2006a. Commonly used caspase inhibitors designed based on substrate specificity profiles lack selectivity. Cell Res 16: 961-963.
9. Berger AB, Witte MD, Denault JB, Sadaghiani AM, Sexton KM, Salvesen GS, Bogyo M. 2006b. Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes. Mol Cell 23: 509-521.
10. Bieth JG. 1984. In vivo significance of kinetic constants of protein proteinase inhibitors. Biochem Med 32: 387-397.
11. Blanchard H, Kodandapani L, Mittl PR, Marco SD, Krebs JF, Wu JC, Tomaselli KJ, Grutter MG. 1999. The three-dimensional structure of caspase-8: An initiator enzyme in apoptosis. Structure 7: 1125-1133.
12. Boucher D, Blais V, Denault JB. 2012. Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 pro-teolysis. Proc Natl Acad Sci 109: 5669-5674.
13. Boulware KT, Daugherty PS. 2006. Protease specificity determination by using cellular libraries of peptide substrates (CLiPS). Proc Natl Acad Sci 103: 7583-7588.
14. Brady KD. 1998. Bimodal inhibition of caspase-1 by arylox-ymethyl and acyloxymethyl ketones. Biochemistry 37: 8508-8515.
15. Brady KD, Giegel DA, Grinnell C, Lunney E, Talanian RV, Wong W, Walker N. 1999. A catalytic mechanism for caspase-1 and for bimodal inhibition of caspase-1 by activated aspartic ketones. Bioorg Med Chem 7: 621-631.
16. Bullok K, Piwnica-Worms D. 2005. Synthesis and characterization of a small, membrane-permeant, caspase-activat-able far-red fluorescent peptide for imaging apoptosis. J Med Chem 48: 5404-5407.
17. Cai SX, Zhang HZ, Guastella J, Drewe J, Yang W, Weber E. 2001. Design and synthesis of rhodamine 110 derivative and caspase-3 substrate for enzyme and cell-based fluorescent assay. Bioorg Med Chem Lett 11: 39-42.
18. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. 1998. Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321.
19. Cen H, Mao F, Aronchik I, Fuentes RJ, Firestone GL. 2008. DEVD-NucView488: A novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells. FASEB J 22: 2243-2252.
20. Chen JM, Rawlings ND, Stevens RA, Barrett AJ. 1998. Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine en-dopeptidases. FEBS Lett 441: 361-365.
21. Crawford ED, Wells JA. 2011. Caspase substrates and cellular remodeling. Annu Rev Biochem 80: 1055-1087.
22. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. 1997. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388: 300-304.
23. Dix MM, Simon GM, Cravatt BF. 2008. Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell 134: 679-691.
24. Dolle RE, Singh J, Rinker J, Hoyer D, Prasad CV, Graybill TL, Salvino JM, Helaszek CT, Miller RE, Ator MA. 1994. Aspartyl a-((1-phenyl-3-(trifluoromethyl)-pyrazol-5-yl) oxy)methyl ketonesas interleukin-1b converting enzyme inhibitors. Significance of the P1 and P3 amido nitrogens for enzyme-peptide inhibitor binding. J Med Chem 37: 3863-3866.
25. Dolle RE, Prasad CV, Prouty CP, Salvino JM, Awad MM, Schmidt SJ, Hoyer D, Ross TM, Graybill TL, Speier GJ, et al. 1997. Pyridazinodiazepines as a high-affinity, P2-P3 peptidomimetic class of interleukin-1b-converting enzyme inhibitor. J Med Chem 40: 1941-1946.
26. Drag M, Salvesen GS. 2010. Emerging principles in prote-ase-based drug discovery. Nat Rev Drug Discov 9: 690-701.
27. Earnshaw WC, Martins LM, Kaufmann SH. 1999. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68: 383-424.
28. Edgington LE, Berger AB, Blum G, Albrow VE, Paulick MG, Lineberry N, Bogyo M. 2009. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat Med 15: 967-973.
29. Edgington LE, Verdoes M, Bogyo M. 2011. Functional imaging of proteases: Recent advances in the design and application of substrate-based and activity-based probes. Curr Opin Chem Biol 15: 798-805.
30. Edgington LE, van Raam BJ, Verdoes M, Wierschem C, Salvesen GS, Bogyo M. 2012. An optimized activity-based probe for the study of caspase-6 activation. Chem Biol 19: 340-352.
31. Ekici OD, Gotz MG, James KE, Li ZZ, Rukamp BJ, Asgian JL, Caffrey CR, Hansell E, Dvorak J, McKerrow JH, et al. 2004. Aza-peptide Michael acceptors: A new class of inhibitors specific for caspases and other clan CD cysteine proteases. J Med Chem 47: 1889-1892.
32. Ekici OD, Li ZZ, Campbell AJ, James KE, Asgian JL, Miko-lajczyk J, Salvesen GS, Ganesan R, Jelakovic S, Grutter MG, et al. 2006. Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10. J Med Chem 49: 5728-5749.
33. Enoksson M, Li J, Ivancic MM, Timmer JC, Wildfang E, Eroshkin A, Salvesen GS, Tao WA. 2007. Identification of proteolytic cleavage sites by quantitative proteomics. J Proteome Res 6: 2850-2858.
34. Evans MJ, Cravatt BF. 2006. Mechanism-based profiling of enzyme families. Chem Rev 106: 3279-3301.
35. Fischer U, Janicke RU, Schulze-Osthoff K. 2003. Many cuts to ruin: A comprehensive update of caspase substrates. Cell Death Differ 10: 76-100.
36. Fonovic M, Bogyo M. 2008. Activity-based probes as a tool for functional proteomic analysis of proteases. Expert Rev Proteomics 5: 721-730.
37. Fuentes-Prior P, Salvesen GS. 2004. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 384: 201-232.
38. Galatsis P, Caprathe B, Downing D, Gilmore J, Harter W, Hays S, Kostlan C, Linn K, Lunney E, Para K, et al. 2010. Inhibition of interleukin-1b converting enzyme (ICE or caspase 1) by aspartyl acyloxyalkyl ketones and aspartyl amidooxyalkyl ketones. Bioorg Med Chem Lett 20: 5089- 5094.
39. Ganesan R, Jelakovic S, Campbell AJ, Li ZZ, Asgian JL, Powers JC, Grutter MG. 2006a. Exploring the S4 and S1 prime subsite specificities in caspase-3 with aza-peptide epoxide inhibitors. Biochemistry 45: 9059-9067.
40. Ganesan R, Mittl PR, Jelakovic S, Grutter MG. 2006b. Extended substrate recognition in caspase-3 revealed by high resolution X-ray structure analysis. J Mol Biol 359: 1378-1388.
41. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. 1998. Inhibition ofhuman caspases by peptide-based and macromolecular inhibitors. J Biol Chem 273: 32608-32613.
42. Garcia-Calvo M, Peterson EP, Rasper DM, Vaillancourt JP, Zamboni R, Nicholson DW, Thornberry NA. 1999. Purification and catalytic properties of human caspase family members. Cell Death Differ 6: 362-369.
43. Grabarek J, Amstad P, Darzynkiewicz Z. 2002. Use of fluo-rescently labeled caspase inhibitors as affinity labels to detect activated caspases. Hum Cell 15: 1-12.
44. Graczyk PP. 2002. Caspase inhibitors as anti-inflammatory and antiapoptotic agents. Prog Med Chem 39: 1-72.
45. Graybill TL, Prouty CP, Speier G, Hoyer D, Dolle RE, He-laszek CT, Ator MA, Uhl J, Strasters J. 1997. a-((Tetro-noyl)oxy)- and a-((Tetramoyl)oxy)methyl ketone inhibitors of the interleukin-1B converting enzyme (ICE). Bioorg Med Chem Lett 7: 41-46.
46. Hardy JA, Lam J, Nguyen JT, O'Brien T, Wells JA. 2004. Discovery of an allosteric site in the caspases. Proc Natl Acad Sci 101: 12461-12466.
47. Harris JL, Backes BJ, Leonetti F, Mahrus S, Ellman JA, Craik CS. 2000. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci 97: 7754-7759.
48. Hawkins CJ, Yoo SJ, Peterson EP, Wang SL, Vernooy SY, Hay BA. 2000. The Drosophila caspase DRONC cleaves following glutamate or aspartate and is regulated by DIAP1, HID, and GRIM. J Biol Chem 275: 27084-27093.
49. Heal WP, Wickramasinghe SR, Tate EW. 2008. Activitybased chemical proteomics: Profiling proteases as drug targets. Curr Drug Discov Technol 5: 200-212.
50. Heal WP, Dang TH, Tate EW. 2011. Activity-based probes: Discovering new biology and new drug targets. Chem Soc Rev 40: 246-257.
51. Hickson J, Ackler S, Klaubert D, Bouska J, Ellis P, Foster K, Oleksijew A, Rodriguez L, Schlessinger S, Wang B, et al. 2010. Noninvasive molecular imaging of apoptosis in vivo using a modified firefly luciferase substrate, Z-DEVD-aminoluciferin. Cell Death Differ 17: 1003-1010.
52. Huber KL, Ghosh S, Hardy JA. 2012. Inhibition of caspase-9 by stabilized peptides targeting the dimerization interface. Biopolymers 98: 451-465.
53. Impens F, Colaert N, Helsens K, Plasman K, Van Damme P, Vandekerckhove J, Gevaert K. 2010. MS-driven protease substrate degradomics. Proteomics 10: 1284-1296.
54. Jadhav U, Ezhilarasan R, Vaughn SF, Berhow MA, Mohanam S. 2007. Iberin induces cell cycle arrest and apoptosis in human neuroblastoma cells. Int J Mol Med 19: 353-361.
55. James KE, Asgian JL, Li ZZ, Ekici OD, Rubin JR, Mikolaj-czyk J, Salvesen GS, Powers JC. 2004. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8. J Med Chem 47: 1553-1574.
56. Kam CM, Abuelyaman AS, Li Z, Hudig D, Powers JC. 1993. Biotinylated isocoumarins, new inhibitors and reagents for detection, localization, and isolation of serine proteases. Bioconjug Chem 4: 560-567.
57. Kato D, Boatright KM, Berger AB, Nazif T, Blum G, Ryan C, Chehade KA, Salvesen GS, Bogyo M. 2005. Activity-based probes that target diverse cysteine protease families. Nat Chem Biol 1: 33-38.
58. Kindermann M, Roschitzki-Voser H, Caglic D, Repnik U, Miniejew C, Mittl PR, Kosec G, Grutter MG, Turk B, Wendt KU. 2010. Selective and sensitive monitoring of caspase-1 activity by a novel bioluminescent activity-based probe. Chem Biol 17: 999-1007.
59. Kushida Y, Hanaoka K, Komatsu T, Terai T, Ueno T, Yoshida K, Uchiyama M, Nagano T.2012. Red fluorescent scaffold for highly sensitive protease activity probes. Bioorg Med Chem Lett 22: 3908-3911.
60. Kuzelova K, Grebenova D, Hrkal Z. 2007. Labeling of apo-ptotic JURL-MK1 cells by fluorescent caspase-3 inhibitor FAM-DEVD-fmk occurs mainly at site(s) different from caspase-3 active site. Cytometry A 71: 605-611.
61. Lazebnik YA. 1997. Oncogene-dependent apoptosis in ex-tractsfromdrug-resistant cells.GenesDev11: 1266-1276.
62. Lee H, Akers WJ, Cheney PP, Edwards WB, Liang K, Culver JP, Achilefu S. 2009. Complementary optical and nuclear imaging of caspase-3 activity using combined activatable and radio-labeled multimodality molecular probe. J Bi-omed Opt 14: 040507.
63. Leyva MJ, Degiacomo F, Kaltenbach LS, Holcomb J, Zhang N, Gafni J, Park H, Lo DC, Salvesen GS, Ellerby LM, et al. 2010. Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. Chem Biol 17: 1189-1200.
64. Li J, Billiar TR, Talanian RV, Kim YM. 1997. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 240: 419-424.
65. Lien S, Pastor R, Sutherlin D, Lowman HB. 2004. A sub-strate-phage approach for investigating caspase specificity. Protein J 23: 413-425.
66. Linton SD. 2005. Caspase inhibitors: A pharmaceutical industry perspective. Curr Top Med Chem 5: 1697-1717.
67. Liu J, Bhalgat M, Zhang C, Diwu Z, Hoyland B, Klaubert DH. 1999. Fluorescent molecular probes V: A sensitive caspase-3 substrate for fluorometric assays. Bioorg Med Chem Lett 9: 3231-3236.
68. Lopez-Otin C, Overall CM. 2002. Protease degradomics: A new challenge for proteomics. Nat Rev Mol Cell Biol 3: 509-519.
69. Lozanov V, Ivanov IP, Benkova B, Mitev V. 2009. Peptide substrate for caspase-3 with 2-aminoacridone as reporting group. Amino Acids 36: 581-586.
70. Luthra S, Fardin B, Dong J, Hertzog D, Kamjoo S, Gebre-mariam S, Butani V, Narayanan R, Mungcal JK, Kupper-mann BD, et al. 2006. Activation of caspase-8 and cas-pase-12 pathways by 7-ketocholesterol in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 47: 5569-5575.
71. Mahrus S, Trinidad JC, Barkan DT, Sali A, Burlingame AL, Wells JA. 2008. Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini. Cell 134: 866-876.
72. Maly DJ, Leonetti F, Backes BJ, Dauber DS, Harris JL, Craik CS, Ellman JA. 2002. Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-car-bamoylmethylcoumarin (ACC) fluorophore. J Org Chem 67: 910-915.
73. Mannick JB, Schonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang K, Gaston B.2001. S-Nitrosylation of mitochon-drial caspases. J Cell Biol 154: 1111-1116.
74. Martin SJ, Green DR. 1995. Protease activation during apoptosis: Death by a thousand cuts? Cell 82: 349-352.
75. Martins LM, Kottke TJ, Kaufmann SH, Earnshaw WC. 1998. Phosphorylated forms ofactivated caspases are present in cytosol from HL-60 cells during etoposide-induced ap-optosis. Blood 92: 3042-3049.
76. Mattos C, Bellamacina CR, Peisach E, Pereira A, Vitkup D, Petsko GA, Ringe D. 2006. Multiple solvent crystal structures: Probing binding sites, plasticity and hydration. J Mol Biol 357: 1471-1482.
77. Maxwell D, Chang Q, Zhang X, Barnett EM, Piwnica-Worms D. 2009. An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apopto-sis imaging. Bioconjug Chem 20: 702-709.
78. McStay GP, Salvesen GS, Green DR. 2008. Overlapping cleavage motif selectivity of caspases: Implications for analysis of apoptotic pathways. Cell Death Differ 15: 322-331.
79. Methot N, Vaillancourt JP, Huang J, Colucci J, Han Y, Me-nard S, Zamboni R, Toulmond S, Nicholson DW, Roy S. 2004. A caspase active site probe reveals high fractional inhibition needed to block DNA fragmentation. J Biol Chem 279: 27905-27914.
80. Mittl PR, Di Marco S, Krebs JF, Bai X, Karanewsky DS, Priestle JP, Tomaselli KJ, Grutter MG. 1997. Structure of recombinant human CPP32 in complex with the tet-rapeptide acetyl-Asp-Val-Ala-Asp fluoromethyl ketone. J Biol Chem 272: 6539-6547.
81. Newton AS, Gloria PM, Goncalves LM, dos Santos DJ, Mor-eira R, Guedes RC, Santos MM. 2010. Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study. Eur J Med Chem 45: 3858-3863.
82. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. 2009. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci 106: 16375-16380.
83. Nicholson DW. 1999. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6: 1028-1042.
84. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al. 1995. Identification and inhibition of the ICE/ CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
85. O'Brien MA, Daily WJ, Hesselberth PE, Moravec RA, Scur-ria MA, Klaubert DH, Bulleit RF, Wood KV. 2005. Homogeneous, bioluminescent protease assays: Caspase-3 as a model. J Biomol Screen 10: 137-148.
86. Odake S, Kam CM, Narasimhan L, Poe M, Blake JT, Kra-henbuhl O, Tschopp J, Powers JC. 1991. Human and murine cytotoxic T lymphocyte serine proteases: Subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochemistry 30: 2217-2227.
87. Pereira NA, Song Z. 2008. Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity. Biochem Biophys Res Commun 377: 873-877.
88. Perry DK, Smyth MJ, Stennicke HR, Salvesen GS, Duriez P, Poirier GG, Hannun YA. 1997. Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem 272: 18530-18533.
89. Petrassi HM, Williams JA, Li J, Tumanut C, Ek J, Nakai T, Masick B, Backes BJ, Harris JL. 2005. A strategy to profile prime and non-prime proteolytic substrate specificity. Bioorg Med Chem Lett 15: 3162-3166.
90. Pop C, Salvesen GS. 2009. Human caspases: Activation, specificity, and regulation. J Biol Chem 284: 21777-21781.
91. Poreba M, Drag M. 2010. Current strategies for probing substrate specificity of proteases. Curr Med Chem 17: 3968-3995.
92. Powers JC, Asgian JL, Ekici OD, James KE. 2002. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev 102: 4639-4750.
93. Puri AW, Broz P, Shen A, Monack DM, Bogyo M. 2012. Caspase-1 activity is required to bypass macrophage apoptosis upon Salmonella infection. Nat Chem Biol 8: 745-747.
94. Rano TA, Timkey T, Peterson EP, Rotonda J, Nicholson DW, Becker JW, Chapman KT, Thornberry NA. 1997. A combinatorial approach for determining protease specificities: Application to interleukin-1b converting enzyme (ICE). Chem Biol 4: 149-155.
95. Rawlings ND, Morton FR, Kok CY, Kong J, Barrett AJ. 2008. MEROPS: The peptidase database. Nucleic Acids Res 36: D320-D325.
96. Rehm M, Dussmann H, Janicke RU, Tavare JM, Kogel D, Prehn JH. 2002. Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process. Role of caspase-3. J Biol Chem 277: 24506-24514.
97. Rozman-Pungercar J, Kopitar-Jerala N, Bogyo M, Turk D, Vasiljeva O, Stefe I, Vandenabeele P, Bromme D, Puizdar V, Fonovic M, et al. 2003. Inhibition of papain-like cys-teine proteases and legumain by caspase-specific inhibitors: When reaction mechanism is more important than specificity. Cell Death Differ 10: 881-888.
98. Sadaghiani AM, Verhelst SH, Bogyo M. 2007. Tagging and detection strategies for activity-based proteomics. Curr Opin Chem Biol 11: 20-28.
99. Salvesen GS, Dixit VM. 1997. Caspases: Intracellular signaling by proteolysis. Cell 91: 443-446.
100. Schilling O, Overall CM. 2008. Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat Biotechnol 26: 685-694.
101. Schweizer A, Briand C, Grutter MG. 2003. Crystal structure of caspase-2, apical initiator of the intrinsic apoptotic pathway. J Biol Chem 278: 42441-42447.
102. Scott FL, Denault JB, Riedl SJ, Shin H, Renatus M, Salvesen GS. 2005. XIAP inhibits caspase-3 and -7 using two binding sites: Evolutionarily conserved mechanism of IAPs. EMBO J 24: 645-655.
103. Serim S, Haedke U, Verhelst SH. 2012. Activity-based probes for the study of proteases: Recent advances and developments. ChemMedChem 7: 1146-1159.
104. Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM, Alnemri ES, Fairman R, Shi Y. 2003. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 11: 519-527.
105. Siegmund B, Zeitz M. 2003. Pralnacasan (vertex pharmaceuticals). IDrugs 6: 154-158.
106. Sleath PR, Hendrickson RC, Kronheim SR, March CJ, Black RA. 1990. Substrate specificity of the protease that processes human interleukin-1b. J Biol Chem 265: 14526- 14528.
107. Smolewski P, Bedner E, Du L, Hsieh TC, Wu JM, Phelps DJ, Darzynkiewicz Z. 2001. Detection of caspases activation byfluorochrome-labeled inhibitors: Multiparameter analysis by laser scanning cytometry. Cytometry 44: 73- 82.
108. Smolewski P, Grabarek J, Lee BW, Johnson GL, Darzynkie-wicz Z. 2002. Kinetics of HL-60 cell entry to apoptosis during treatment with TNF-a or camptothecin assayed by the stathmo-apoptosis method. Cytometry 47: 143- 149.
109. Snipas SJ, Drag M, Stennicke HR, Salvesen GS. 2008. Activation mechanism and substrate specificity of the Droso-phila initiator caspase DRONC. Cell Death Differ 15: 938-945.
110. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee RA, Robbins PD, Fernandes-Alnemri T, Shi Y, et al. 2001. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apo-ptosis. Nature 410: 112-116.
111. Stennicke HR, Salvesen GS. 1997. Biochemical characteristics of caspases-3, -6, -7, and -8. J Biol Chem 272: 25719- 25723.
112. Stennicke HR, Renatus M, Meldal M, Salvesen GS. 2000. Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8. Biochem J 350 (Pt 2): 563-568.
113. Sun J, Bottomley SP, Kumar S, Bird PI. 1997. Recombinant caspase-3 expressed in Pichia pastoris is fully activated and kinetically indistinguishable from the native enzyme. Biochem Biophys Res Commun 238: 920-924.
114. Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW. 1997. Substrate specificities of caspase family proteases. J Biol Chem 272: 9677-9682.
115. Talanian RV, Brady KD, Cryns VL. 2000. Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery. J Med Chem 43: 3351-3371.
116. Tang Y, Wells JA, Arkin MR. 2011. Structural and enzymatic insights into caspase-2 protein substrate recognition and catalysis. J Biol Chem 286: 34147-34154.
117. Teodori L, Grabarek J, Smolewski P, Ghibelli L, Bergamaschi A, De Nicola M, Darzynkiewicz Z. 2002. Exposure of cells to static magnetic field accelerates loss of integrity of plasma membrane during apoptosis. Cytometry 49: 113-118.
118. Thornberry NA. 1994. Interleukin-1b converting enzyme. Methods Enzymol 244: 615-631.
119. Thornberry NA, Molineaux SM. 1995. Interleukin-1b converting enzyme: A novel cysteine protease required for IL-1b production and implicated in programmed cell death. Protein Sci 4: 3-12.
120. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. 1992. A novel heterodimeric cysteine protease is required for interleukin-1b processing in monocytes. Nature 356: 768-774.
121. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, et al. 1997. A combinatorial approach defines specificities of members of the caspase family and Granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 272: 17907-17911.
122. Timmer JC, Salvesen GS. 2007. Caspase substrates. Cell Death Differ 14: 66-72.
123. Timmer JC, Zhu W, Pop C, Regan T, Snipas SJ, Eroshkin AM, Riedl SJ, Salvesen GS. 2009. Structural and kinetic determinants of protease substrates. Nat Struct Mol Biol 16: 1101-1108.
124. Tu S, McStay GP, Boucher LM, Mak T, Beere HM, Green DR. 2006. In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apopto-sis. Nat Cell Biol 8: 72-77.
125. Valero A, Merino F, Wolbers F, Luttge R, Vermes I, Ander-sson H, van den Berg A. 2005. Apoptotic cell death dynamics of HL60 cells studied using a microfluidic cell trap device. Lab Chip 5: 49-55.
126. Van Damme P, Martens L, Van Damme J, Hugelier K, Staes A, Vandekerckhove J, Gevaert K. 2005. Caspase-specific and nonspecific in vivo protein processing during Fas-induced apoptosis. Nat Methods 2: 771-777.
127. Van Noorden CJ. 2001. The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochem 103: 241-251.
128. Velazquez-Delgado EM, Hardy JA. 2012. Zinc-mediated al-losteric inhibition of caspase-6. J Biol Chem 287: 36000- 36011.
129. Vercammen D, van de Cotte B, De Jaeger G, Eeckhout D, Peter Casteels P, Vandepoele K, Vandenberghe I, Van Beeumen J, Inzé D, Van Breusegem F. 2004. Type-II meta-caspases Atmc4 and Atmc9 of Arabidopsis thaliana cleave substrates after arginine and lysine. J Biol Chem 279: 45329-45336.
130. Walters J, Pop C, Scott FL, Drag M, Swartz P, Mattos C, Salvesen GS, Clark AC. 2009. A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis. Biochem J 424: 335-345.
131. Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, Decker C, Charifson P, Weber P, Germann UA, et al. 2007. (S)-1-((S)-2-f[1-(4-amino-3-chloro-phenyl)-methanoyl]-aminog-3,3-dimethyl-butanoy l)-pyrroli-dine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetra-hydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the releaseof IL-1b and IL-18.J Pharmacol Exp Ther 321: 509-516.
132. Wei Y, Fox T, Chambers SP, Sintchak J, Coll JT, Golec JM, Swenson L, Wilson KP, Charifson PS. 2000. The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity. Chem Biol 7: 423-432.
133. Winssinger N, Damoiseaux R, Tully DC, Geierstanger BH, Burdick K, Harris JL. 2004. PNA-encoded protease substrate microarrays. Chem Biol 11: 1351-1360.
134. Wu X, Simone J, Hewgill D, Siegel R, Lipsky PE, He L. 2006. Measurement of two caspase activities simultaneously in living cells by a novel dual FRET fluorescent indicator probe. Cytometry A 69: 477-486.
135. Xu G, Shin SB, Jaffrey SR. 2009. Global profiling of protease cleavage sites by chemoselective labeling of protein N-termini. Proc Natl Acad Sci 106: 19310-19315.
136. Yin XM, Dong Z. 2009. Essentials of apoptosis: A guide for basic and clinical research, 2nd ed. Humana Press, Totowa, NJ.
137. Zhang HZ, Kasibhatla S, Guastella J, Tseng B, Drewe J, Cai SX. 2003. N-Ac-DEVD-N0-(Polyfluorobenzoyl)-R110: Novel cell-permeable fluorogenic caspase substrates for the detection of caspase activity and apoptosis. Bioconjug Chem 14: 458-463.
138. Zhou D, Chu W, Rothfuss J, Zeng C, Xu J, Jones L, Welch MJ, Mach RH. 2006. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett 16: 5041-5046.
139. Zhou D, Chu W, Chen DL, Wang Q, Reichert DE, Rothfuss J, D'Avignon A, Welch MJ, Mach RH. 2009. [18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: Synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98. Org Biomol Chem 7: 1337-1348.